These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26945298)

  • 1. Paying for On-Patent Pharmaceuticals: Limit Prices and the Emerging Role of a Pay for Outcomes Approach.
    Fuller RL; Goldfield N
    J Ambul Care Manage; 2016; 39(2):143-9. PubMed ID: 26945298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Reduce Prescription Drug Prices: First, Do No Harm.
    Atlas S
    Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
    [No Abstract]   [Full Text] [Related]  

  • 4. Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.
    Sachs R; Bagley N; Lakdawalla DN
    J Health Polit Policy Law; 2018 Feb; 43(1):5-18. PubMed ID: 28972020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug Prices.
    White EK
    Food Drug Law J; 2017; 72(1):189-224. PubMed ID: 29140658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
    Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
    Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
    Bendicksen L; Rome BN; Avorn J; Kesselheim AS
    Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
    Balderrama F; Schwartz LJ; Longo CJ
    Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 10. Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
    Conti RM; David FS
    F1000Res; 2020; 9():707. PubMed ID: 33204410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. California's Drug Transparency Law: Navigating The Boundaries Of State Authority On Drug Pricing.
    Gudiksen KL; Brown TT; Whaley CM; King JS
    Health Aff (Millwood); 2018 Sep; 37(9):1503-1508. PubMed ID: 30179546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies.
    Baker D
    J Law Med Ethics; 2021; 49(1):25-29. PubMed ID: 33966644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the literature on reference pricing.
    López-Casasnovas G; Puig-Junoy J
    Health Policy; 2000 Nov; 54(2):87-123. PubMed ID: 11094265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
    Gronde TV; Uyl-de Groot CA; Pieters T
    PLoS One; 2017; 12(8):e0182613. PubMed ID: 28813502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
    Biot J; Fasano C; Dos Santos C
    Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.